Ocuphire Pharma(OCUP) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update - Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision - - Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 - - OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease - - Supplem ...